Human IL-23R Protein, Fc Tag (MALS verified)
分子別名(Synonym)
IL-23R,IL-23 Receptor
表達區(qū)間及表達系統(tǒng)(Source)
Human IL-23R, Fc Tag (ILR-H5254) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Gly 355 (Accession # Q5VWK5-1).
Predicted N-terminus: Gly 24
蛋白結構(Molecular Characterization)

This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 64.5 kDa. The protein migrates as 90-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.


背景(Background)
白介素23受體(IL-23R)是一種I型細胞因子受體,IL-23R與受體分子IL12RB1/IL12Rbeta1配對,兩者都是IL23A信號傳導所必需的。此外,IL-23R與Janus激酶2(JAK2)組成性結合,并以配體依賴的方式與轉錄激活劑STAT3結合。此外,IL-23R可能通過激活Jak-Stat信號級聯來介導T細胞、NK細胞和可能的某些巨噬細胞/髓細胞刺激。至于IL-23,它可能與自身免疫性炎癥性疾病有關,并對腫瘤發(fā)生具有重要意義。
關鍵字: IL-23R;IL-23R蛋白;IL-23R重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下擁有品牌ACROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。